Baxter International

When researching Baxter International, analysts typically begin with its Health Care sector positioning and Health Care Equipment industry dynamics. Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

The company reports trailing twelve-month revenue of $2.70B and net loss of $15.00M. Key metrics include a return on equity of -0.3%, a debt-to-equity ratio of 2.29.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for BAX to support both active traders and long-term investors.